OncoMatch/Clinical Trials/NCT04875611
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Is NCT04875611 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Opdivo for nasopharyngeal cancer.
Treatment: Opdivo — Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Previous, documented failure on platinum-based chemotherapy or progression of the disease during platinum-based chemotherapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or anti-ICOS directed agent
Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent
Cannot have received: bone marrow or solid organ transplantation
Patient with prior bone marrow or solid organ transplantation.
Lab requirements
Blood counts
hemoglobin < 9 g/dl, platelets < 100 x 10^9 /L, ANC < 1.0 x 10^9 /L
Kidney function
eGFR < 30 ml/min/m2
Liver function
AST and/or ALT > 2.5 x ULN (> 5 x ULN in patients with documented liver metastases); total bilirubin > 1.5 x ULN (acceptable if direct bilirubin < 35%); albumin < 2.5 g/dL
Cardiac function
ejection fraction in echocardiography < 50%
Presence of renal insufficiency defined as eGFR < 30 ml/min/m2; Presence of liver disfunction, defined as level of AST and/or ALT > 2.5 x ULN (> 5 x ULN in patients with documented liver metastases); total bilirubin > 1.5 x ULN (acceptable if direct bilirubin < 35%) or albumin < 2.5 g/dL; Abnormalities in blood count such as: hemoglobin < 9 g/dl, platelets < 100 x 10^9 /L, ANC <1.0 x 10^9 /L; Ejection fraction in echocardiography < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify